Pembrolizumab Plus Quad-Shot Radiotherapy: A Promising Approach for Recurrent, Unresectable Head and Neck Cancer
Highlight
This phase 2 nonrandomized trial suggests that combining pembrolizumab, an immune checkpoint inhibitor, with low-dose hypofractionated quad-shot radiotherapy (QSRT) is feasible and may enhance anti-tumor efficacy in patients with recurrent, unresectable, or metastatic head and neck squamous cell carcinoma (RUM HNSCC). Among evaluable patients, an overall response rate of 47% was observed, with median progression-free survival (PFS) of 11.5 months and overall survival (OS) of 15.3 months. The regimen had a manageable safety profile without substantial increases in patient-reported adverse events over time, supporting further exploration in randomized trials.
Study Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.